Compound screening in cell-based models of tau inclusion formation: Comparison of primary neuron and HEK293 cell assays.

ABSTRACT: The hallmark pathological features of Alzheimer's disease (AD) brains are senile plaques, comprising β-amyloid (Aβ) peptides, and neuronal inclusions formed from tau protein. These plaques form 10-20 years before AD symptom onset, whereas robust tau pathology is more closely associated with symptoms and correlates with cognitive status. This temporal sequence of AD pathology development, coupled with repeated clinical failures of Aβ-directed drugs, suggests that molecules that reduce tau inclusions have therapeutic potential. Few tau-directed drugs are presently in clinical testing, in part because of the difficulty in identifying molecules that reduce tau inclusions. We describe here two cell-based assays of tau inclusion formation that we employed to screen for compounds that inhibit tau

SUBMITTER: Crowe A 

PROVIDER: S-EPMC7086036 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature